Fresenius Kabi Offers Research Award

Fresenius Kabi is seeking applicants for a new $100,000 U.S. research award to support the advancement of the therapeutic areas of photopheresis, and red cell exchange. “Fresenius Kabi along with its Fenwal subsidiary are committed to supporting innovative science that provides hope through the advancement of photopheresis and red cell exchange,” said William Cork, executive vice president and chief technology officer for the Fresenius Kabi Medical Devices division.
 
Photopheresis therapy involves using advanced blood-separation techniques to introduce light-activated drugs to the blood, expose the blood to ultraviolet light outside the body, and return the treated blood to the patient. This technique is currently used to treat rare cancers and immune disorders. Red cell exchange involves removing and replacing a patient’s red cells using specialized blood-separation equipment and medicines to help treat sickle cell disease and other conditions.
 
Interested applicants can learn more about the Fresenius Kabi award and the eligibility criteria at www.FreseniusKabiScience.com. The application deadline is December 15, 2013.